ATOPIC DERMATITIS REPORT
KEY LEARNINGS FROM PHESI’S ANALYSIS
OF PHASE 3 CLINICAL TRIALS
Phase 3 trials in multiple indications are heading for avoidable failure. Overly complex trial design, coupled with a lack of real-world data integration, is leading to investigator site saturation and increased burden on patients and investigators. To highlight the systemic issues, Phesi has published a new report using data from its award-winning AI-powered Trial Accelerator™ platform to analyse phase 3 studies in atopic dermatitis. A particularly active indication in development currently, atopic dermatitis ranks second after non-small cell lung cancer, with 18 active trials.
See the data and read the report
Get our latest content
2024 Most Studied Disease areas
Phesi’s annual global analysis of 67,469 recruiting clinical trials shows that breast cancer is the world’s most studied disease for the fourth year running. The data reveals one in three clinical trials were terminated during Phase II, a 50% increase from pre-COVID 19 levels. This represents tens of millions of dollars that could be saved by using data science, AI and clinical data analytics to deliver greater precision in trial design and execution.
Digital Patient Profile Catalogue
Leveraging global data from more than 132 million patients, Trial Accelerator™ generates a detailed picture of the patient for any indication, ensuring greater precision in trial design and execution.
Nature Publication
Read our Nature publication to discover the potential of AI-powered digital twins to replace external control arms in clinical trials.